<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144088</url>
  </required_header>
  <id_info>
    <org_study_id>CS05082</org_study_id>
    <nct_id>NCT04144088</nct_id>
  </id_info>
  <brief_title>Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia.</brief_title>
  <official_title>Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia. A Randomized Placebo-Controlled Double-Blinded Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To testify the efficacy and safety of traditional Chinese formulae, &quot;Wu-Ling San&quot; and
      &quot;Yin-Chen Wu-Ling San&quot; for patients with hyperuricemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of hyperuricemia and gout is increasing in Taiwan. It is probably contributed
      by adapting to Western diet and lifestyle. Previous studies have demonstrated the
      relationship between hyperuricemia with hypertension, metabolic syndrome, cardiovascular
      disease and chronic renal disease. While Western medicine shows promising effects in treating
      hyperuricemia and gout, we are searching for an alternative in traditional Chinese medicine
      with both safety and efficacy in treating hyperuricemia.

      We conducted a randomized double-blinded placebo-controlled clinical trial in adults with
      hyperuricemia. Sixty patients with serum uric acid level more than 8 mg/dl were enrolled.
      Patients were then randomized into three arms: Traditional Chinese Medicine formulae:
      &quot;Wu-Ling San&quot;, &quot;Yin-Chen Wu-Ling San&quot; or placebo for 4 weeks. Efficacy and safety were
      evaluated at Week 2, 4 and 8. Primary endpoint was the serum uric acid&lt;6 mg/dL at Week 4.
      Secondary endpoints were the differences between groups in serum uric acid at Week 2 and 8,
      serum SGPT, SGOT, creatinine, total cholesterol, triglycerides, HDL, LDL, fasting blood
      glucose, body weight, blood pressures and frequency of gouty attack at Week 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2006</start_date>
  <completion_date type="Actual">June 30, 2007</completion_date>
  <primary_completion_date type="Actual">June 30, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Uric Acid&lt;6 mg/dL at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>The number of patient serum uric acid &lt;6 mg/dL at week 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Serum Uric Acid at Week 2</measure>
    <time_frame>week 0, week 2</time_frame>
    <description>The investigators use serum uric acid to compared the difference between the week 2 and week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Serum Uric Acid at Week 8</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>The investigators use serum uric acid to compared the difference between the week 8 and week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Blood Sugar at Week 4</measure>
    <time_frame>week 0, week 4</time_frame>
    <description>The investigators use blood sugar to compared the difference between the week 4 and week 0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Wu Ling San</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug : Wu Ling San Extract Granules &quot;Sun-Ten&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yin-Chen Wu Ling San</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug : Yin-Chen-Wu-Ling-San Extract Power &quot;SUN-TEN&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug : 1/10 Wu Ling San</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wu Ling San</intervention_name>
    <description>assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.</description>
    <arm_group_label>Wu Ling San</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yin-Chen Wu Ling San</intervention_name>
    <description>assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.</description>
    <arm_group_label>Yin-Chen Wu Ling San</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  serum uric acid &gt; 8 mg/dL

        Exclusion Criteria:

          -  1. gout attack within 2 weeks before baseline 2. drug for control urine acid must be
             stable dose within 2 weeks before baseline
             (e.g.allopurinol、benzbromarone、probenecid、sulfinpyrazone) 3. subject taking the drug
             involved azathioprine、aspirin (&gt;325
             mg)、atorvastatin、fenofibrate、losartan、thiazide、systemic corticosteroid、estrogen、oral
             contraceptive pills 4. serum creatinine &gt; 3.0 mg/dL 5. GPT &gt; 100 mg/dL 6. Pregnant or
             breast-feeding women 7. Chemotherapy or radiation therapy in cancer patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Ching Wei, Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <results_first_submitted>November 15, 2019</results_first_submitted>
  <results_first_submitted_qc>November 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2019</results_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>Cheng-Chung Wei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Wu Ling San</title>
          <description>Drug : Wu Ling San Extract Granules &quot;Sun-Ten&quot;
Wu Ling San: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Yin-Chen Wu Ling San</title>
          <description>Drug : Yin-Chen-Wu-Ling-San Extract Power &quot;SUN-TEN&quot;
Yin-Chen Wu Ling San: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Drug : 1/10 Wu Ling San
Placebo: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Wu Ling San</title>
          <description>Drug : Wu Ling San Extract Granules &quot;Sun-Ten&quot;
Wu Ling San: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Yin-Chen Wu Ling San</title>
          <description>Drug : Yin-Chen-Wu-Ling-San Extract Power &quot;SUN-TEN&quot;
Yin-Chen Wu Ling San: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Drug : 1/10 Wu Ling San
Placebo: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="13.9"/>
                    <measurement group_id="B2" value="42.5" spread="14.4"/>
                    <measurement group_id="B3" value="47.3" spread="15.3"/>
                    <measurement group_id="B4" value="48.4" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric Acid</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.4" spread="1.4"/>
                    <measurement group_id="B2" value="9.1" spread="2.1"/>
                    <measurement group_id="B3" value="8.9" spread="1.6"/>
                    <measurement group_id="B4" value="9.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Uric Acid (24hr)</title>
          <units>gm/24hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.6" spread="174.7"/>
                    <measurement group_id="B2" value="109.2" spread="74.6"/>
                    <measurement group_id="B3" value="430.1" spread="1002.8"/>
                    <measurement group_id="B4" value="233.6" spread="595.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.2" spread="13.3"/>
                    <measurement group_id="B2" value="73.0" spread="10.5"/>
                    <measurement group_id="B3" value="72.4" spread="10.5"/>
                    <measurement group_id="B4" value="72.2" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Uric Acid&lt;6 mg/dL at Week 4</title>
        <description>The number of patient serum uric acid &lt;6 mg/dL at week 4</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wu Ling San</title>
            <description>Drug : Wu Ling San Extract Granules &quot;Sun-Ten&quot;
Wu Ling San: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Yin-Chen Wu Ling San</title>
            <description>Drug : Yin-Chen-Wu-Ling-San Extract Power &quot;SUN-TEN&quot;
Yin-Chen Wu Ling San: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Drug : 1/10 Wu Ling San
Placebo: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Uric Acid&lt;6 mg/dL at Week 4</title>
          <description>The number of patient serum uric acid &lt;6 mg/dL at week 4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Serum Uric Acid at Week 2</title>
        <description>The investigators use serum uric acid to compared the difference between the week 2 and week 0</description>
        <time_frame>week 0, week 2</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Serum Uric Acid at Week 8</title>
        <description>The investigators use serum uric acid to compared the difference between the week 8 and week 0</description>
        <time_frame>week 0, week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Blood Sugar at Week 4</title>
        <description>The investigators use blood sugar to compared the difference between the week 4 and week 0</description>
        <time_frame>week 0, week 4</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Wu Ling San</title>
          <description>Drug : Wu Ling San Extract Granules &quot;Sun-Ten&quot;
Wu Ling San: assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Yin-Chen Wu Ling San</title>
          <description>Drug : Yin-Chen-Wu-Ling-San Extract Power &quot;SUN-TEN&quot;
Yin-Chen Wu Ling San: assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Drug : 1/10 Wu Ling San
Placebo: 1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated of WBC (WBC: 12920/mm3)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>fecal frequency increased but not diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>muscle soreness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated of GPT (GPT &gt; 41 IU/L)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>gout attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated of creatine ( Cr: 3.7mg/dl)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>asthma attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>seborrheic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Burns</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cheng Chung Wei</name_or_title>
      <organization>Chung Shan Medical University Hospital</organization>
      <phone>+886-4-24739595 ext 34718</phone>
      <email>wei3228@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

